Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Astellas’ Yoshitsugu Shitaka Elected as New FIRM Chair
June 20, 2023
- Lag and Loss Blamed on Drug Pricing System, JPMA Set to Get Involved in Corrective Steps: President
June 15, 2023
- Over 70% of Pharmacies Fill “Zero” Refill Prescriptions per Month: FPMAJ Survey
June 13, 2023
- FPMAJ Demands Better Criteria for Selecting Comparator Drugs to Factor in Disease Features and Product Positioning
June 12, 2023
- PMP Company Criteria Mar Market Attractiveness, Scrap Them: FPMAJ
June 12, 2023
- Tide Has Changed, but That Doesn’t Erase Concerns: FPMAJ Drug Pricing Chief
June 12, 2023
- Regenerative Medicine Group Hails Expert Panel’s Proposal on New Pricing Method for Innovative Therapies
June 9, 2023
- JMA Renews Opposition for Health Coverage Review for Pharmaceuticals
June 8, 2023
- Pharma Hails Expert Panel Report, Looks for Govt Leadership to Execute Reforms
June 7, 2023
- Industry’s Concerns Beginning to Sink in among Policymakers: JPMA Committee Chair
June 7, 2023
- Protect Info for Off-Patent Brands Even after Market Exit: JEMA
May 29, 2023
- Eisai’s Yasushi Okada Becomes FPMAJ Chairman
May 26, 2023
- New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
- 12 Medical and Nursing Care Groups Demand Responses to Inflation, Wage Hikes
May 26, 2023
- Mitsubishi Tanabe’s Ueno Elected as New JPMA President
May 26, 2023
- Supplies of 15% of Drugs Restricted, Generics Account for 80%: FPMAJ
May 24, 2023
- Industry, Academia Groups Applaud Govt’s New Biosimilar Goal, but Fret Pricing, Biosame Issues
May 19, 2023
- Prioritize Cardiovascular Disease on Health Policy Agenda: CfHH to G7
May 15, 2023
- Discuss Multi-Faceted Evaluation of Drugs Ahead of Lecanemab Approval: Policy Veterans’ Group
May 10, 2023
- JPMA Nudges Govt to Take Special Measures for Infectious Disease Biz
May 9, 2023
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…